CBD Oil and Pain: What Does the Human Research Actually Show?

Search online for CBD and pain and you will find confident claims that CBD reduces inflammation, blocks pain signals or provides natural pain relief. The human evidence is much more complicated.

CBD, or cannabidiol, is being investigated in several areas of pain research, but laboratory findings, animal studies and personal experiences are not the same as evidence that a CBD food supplement treats pain in people. In the UK, ordinary CBD oils sold as foods or food supplements should not be presented as medicines or with unauthorised pain-relief claims.

What does NICE say about CBD for chronic pain?

For a UK reader, NICE is a useful place to start. Current NICE guidance on cannabis-based medicinal products says CBD should not be offered to adults to manage chronic pain unless it is part of a clinical trial. NICE reviewed the guideline again in May 2025 and did not change that recommendation.

That does not mean researchers have concluded CBD can never influence pain. It means the evidence is not sufficiently consistent or convincing for NICE to recommend CBD as a chronic-pain treatment.

CBD and arthritis pain

A randomised, double-blind, placebo-controlled trial in people with hand osteoarthritis or psoriatic arthritis tested 20–30 mg of CBD per day for 12 weeks. Researchers found no clinically or statistically significant difference in pain between CBD and placebo. Read the trial on PubMed.

Another placebo-controlled trial studied painful knee osteoarthritis using 600 mg of CBD per day alongside paracetamol for eight weeks. Pain improved in both groups, but CBD did not outperform placebo. Adverse events were more frequent with CBD, and rises in certain liver enzymes were also more common in that group. Read the knee osteoarthritis trial.

These results are a useful reminder that testimonials and before-and-after experiences cannot establish effectiveness. Placebo-controlled trials are designed to separate an intervention's effect from natural symptom fluctuation and other influences.

What about CBD for back pain?

The evidence specifically for CBD alone and back pain is limited. In the CANBACK trial, 100 people presenting to an emergency department with acute non-traumatic lower-back pain received either 400 mg oral CBD or placebo alongside standard care. Two hours later, CBD was not superior to placebo for pain, and rescue analgesia and length of stay were similar between groups. Read the CANBACK trial.

Acute emergency-department back pain is not the same as chronic back pain, so this result should not be stretched beyond the population studied. Equally, it does not provide evidence that ordinary consumer CBD oil treats chronic lower-back pain.

Fibromyalgia: another important negative trial

A 2026 placebo-controlled trial studied 200 people with fibromyalgia. Participants received either 50 mg plant-derived CBD per day or placebo for 24 weeks. At the end of the trial, pain improved more in the placebo group than in the CBD group, and the researchers concluded that the findings did not support CBD as an analgesic supplement for fibromyalgia. Read the fibromyalgia trial.

Is all the human evidence negative?

No. Research is continuing, and different types of pain may not respond in the same way. A 2026 randomised, double-blind, placebo-controlled crossover trial investigated high-dose CBD for chronic neuropathic pain after spinal-cord injury. CBD was titrated up to 800 mg per day. The trial reported a modest reduction in self-reported pain intensity compared with placebo and the researchers said the finding supports further research. Read the spinal-cord-injury trial.

But a study in a specific neuropathic-pain population using high-dose, clinically supervised CBD should not be turned into the blanket statement that retail CBD oil “relieves nerve pain”.

Why the dose difference matters

Clinical trials may use tens or hundreds of milligrams of CBD per day under controlled conditions. That does not mean consumers should copy those doses using retail CBD food supplements.

The Food Standards Agency currently advises healthy adults to limit CBD from food to 10 mg per day. The FSA also advises that people taking medication, children, and people who are pregnant, breastfeeding or trying to conceive should avoid CBD unless under medical direction.

This makes it particularly misleading to take the result of a trial using 400 mg, 600 mg or 800 mg of CBD and imply that a consumer CBD oil can be expected to produce the same outcome.

CBD can also interact with medicines

CBD is not automatically risk-free because it is plant-derived. The FSA notes that CBD can interact with certain medicines and advises people taking medication not to use CBD unless under medical direction.

If somebody is dealing with persistent or unexplained pain, especially while taking prescription medication, a GP, pharmacist or other qualified healthcare professional is a more appropriate source of treatment advice than a retail CBD article.

What can we reasonably conclude about CBD and pain?

The most accurate answer at present is that CBD is an active area of pain research, but the human evidence is mixed and depends heavily on the type of pain, formulation, dose and study design.

Several placebo-controlled trials have failed to show a meaningful analgesic effect, including studies involving arthritis, fibromyalgia and acute lower-back pain. Other research continues to investigate whether CBD might have a role in particular pain populations.

That is very different from saying CBD has been proven to treat chronic pain generally.

What should UK CBD shoppers look for?

If you choose to buy a CBD food supplement, it makes more sense to judge product quality and transparency than to choose one because it promises to relieve a medical condition.

Look for clear information about CBD content, concentration in mg/ml, ingredients and independent laboratory information. Our COA buyer guide explains how to read laboratory information without treating a certificate as proof of medical effectiveness.

If you are comparing concentrations, our CBD oil strength guide explains percentages and mg/ml. A higher percentage means a higher concentration of CBD in the liquid; it does not mean the product is clinically proven to work better for pain.

For practical use information, see our beginner's guide to using CBD oil. For the regulatory picture, see Is CBD Legal in the UK?.

The bottom line

CBD research deserves neither miracle claims nor automatic dismissal. There are plausible reasons to study cannabidiol and research is continuing, but several well-designed human trials have found no advantage over placebo for pain outcomes.

Current NICE guidance does not recommend CBD for managing chronic pain outside a clinical trial. For consumer CBD foods, the FSA also states there are no authorised health claims for pain, anxiety or sleep.

The sensible distinction is between research about CBD and claims about a particular CBD product. We can discuss the first. We should not use it to manufacture the second.

This article is for general information only and is not medical advice. Valley CBD products are sold as food supplements and are not intended to diagnose, treat, cure or prevent disease. If you have persistent pain, a diagnosed medical condition or take medication, speak with a qualified healthcare professional.